🇺🇸 Genotonorm (Somatropin) in United States

21 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Condition Aggravated — 3 reports (14.29%)
  2. Acidosis — 2 reports (9.52%)
  3. Anaemia — 2 reports (9.52%)
  4. Cyst — 2 reports (9.52%)
  5. Cytolytic Hepatitis — 2 reports (9.52%)
  6. Epilepsy — 2 reports (9.52%)
  7. Post Procedural Complication — 2 reports (9.52%)
  8. Renal Failure Acute — 2 reports (9.52%)
  9. Respiratory Distress — 2 reports (9.52%)
  10. Vomiting — 2 reports (9.52%)

Source database →

Other Endocrinology approved in United States

Frequently asked questions

Is Genotonorm (Somatropin) approved in United States?

Genotonorm (Somatropin) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Genotonorm (Somatropin) in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.